NanoLogix Provides 6-hour MRSA Results at UTHSC - Houston. Welcomes New Science Advisory Board Members

Board members bring expertise in obstetrics, gynecology, infectious diseases, microbiology, and veterinary medicine.

HUBBARD, Ohio--(BUSINESS WIRE)-- NanoLogix (OTC MARKETS: NNLX), a biotechnology innovator in the rapid detection and identification of live-cell microorganisms, announces preliminary results of MRSA (Methicillin-resistant Staphylococcus aureus) testing at the University of Texas Health Science Center - Houston. Dr. Jonathan Faro, M.D., Ph.D. has found NanoLogix technology is able to deliver results for MRSA in 6 hours, as opposed to conventional culture-based testing wait times of 24 to 48 hours. Dr. Faro is lead researcher in an ongoing Group B Streptococcus (GBS) clinical trial using NanoLogix test kits at UTHSC. Scientific papers detailing the first two phases of the GBS clinical trial are currently being submitted for publication in peer-reviewed journals.

An interview with Dr. Faro explaining his rapid live-cell results can be found at

NanoLogix Announces New Science Advisory Board Members

NanoLogix is pleased to welcome four exceptionally talented individuals to its Science Advisory Board. New members include Dr. Megan Barnhizer, D.V.M.; Dr. Sebastian Faro, M.D., Ph.D.; and Dr. Allan Katz, M.D. and Dr. Gwen R. Acker Wood, Ph.D., J.D. They join existing Science Board members Ahmer Kodvawala, M.S., M.B.A.; Hilda Diaz, M.S.; and Dr. Clifford Watts, M.D.

"We are very pleased to welcome these new members to the Science Advisory Board,�said Bret Barnhizer, NanoLogix CEO. “The new members add depth and valuable expertise to our SAB as the UTHSC - Houston approaches the conclusion of our GBS clinical trial and we begin the application process for FDA approval.�

Group B Strep is one of the leading health threats for newborns. Current methods for detection and identification take 48 to 72+ hours for results. The new technology from NanoLogix enables detection, identification, and determination of antibiotic sensitivity in 6 hours or less.

Dr. Allan Katz, M.D., professor and Vice-Chairman of Obstetrics and Gynecology at the University of Texas Medical School in Houston, and chief of Gynecology at Hermann Memorial Hospital in Houston stated, “We have relied far too long on traditional culture based technology, and this practice has undoubtedly contributed towards the development of microbial resistance. The technology offered by NanoLogix is exciting as it promises more rapid results in a time when it most matters to the patient. It also holds vast potential as the technology extends beyond GBS and MRSA and tests can be performed by almost anyone, in any corner of the world.�/p>

Dr. Sebastian Faro, M.D., Chief of Obstetrics and Gynecology at LBJ Hospital in Houston, Texas, said, “This is an extremely exciting time to be working on the development of diagnostic tests to identify pathogenic bacteria in a rapid manner. This technology from NanoLogix will revolutionize the process of identifying disease causing bacteria and facilitate a more direct approach in choosing appropriate antibiotic therapy.�

NanoLogix New Science Advisory Board Members

Megan Barnhizer, D.V.M.

Dr. Megan Barnhizer has been a veterinarian in clinical practice since graduating from the Ohio State University College of Veterinary Medicine in 1999. Her addition to the Science Advisory Board comes at a time of marked increase in interest in NanoLogix detection and diagnostic technologies from international and domestic corporations, agencies and organizations with a focus on livestock and animal husbandry.

Sebastian Faro, M.D., Ph.D.

Dr. Sebastian Faro brings an extensive body of knowledge concerning obstetrics, gynecology, and infectious diseases to the NanoLogix Science Advisory Board. Dr. Faro is Chief of Obstetrics and Gynecology at LBJ Hospital in Houston, Texas. He is also the current Vice-Chair of the Obstetrics, Gynecology, and Reproductive Sciences Department at the University of Texas Health Science Center in Houston. Dr. Faro has published at least 149 articles in peer-reviewed medical publications and served as Editor-in-Chief of the Infectious Diseases in Obstetrics and Gynecology journal for 13 years.

Allan Katz, M.D.

Dr. Allan Katz brings to the advisory board over forty years of experience in the fields of women’s health and pregnancy, including the management of high risk pregnancies. Dr. Katz is a Robert K. Creasy Professor and Vice-Chairman of Obstetrics and Gynecology at the University of Texas Medical School at Houston. Dr. Katz is also Chief of Gynecology at Hermann Memorial Hospital.

Gwen R. Acker Wood, Ph.D. J.D.

Gwen R. Acker Wood is a U.S. and foreign patent attorney, who brings a wealth of medical, biotechnology and life sciences patent experience to NanoLogix. Dr. Wood handles patent filings for NanoLogix through her firm, Acker Wood IP Law. Prior to becoming a patent attorney, Dr. Wood was a research scientist in the areas of neurochemistry and psychoimmunology. In addition, she served as an adjunct professor of biology, nutritional science and advanced pathophysiology at New York University, as well as adjunct professor of biology and advanced pathophysiology at Duquesne University.

More information on the NanoLogix Science Advisory Board can be found here or by going to

NanoLogix General Shareholder Meeting Rescheduled

The NanoLogix general shareholder meeting is being rescheduled and will be held in the middle of September 2011. Additional details concerning the date and time of the meeting will be announced as September grows closer. This shareholder meeting will be held virtually, through the Broadridge Virtual Shareholder Meeting service. Further information regarding the process can be found at

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit

More information on NanoLogix is available at:

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.


Media Contact:
Lisa Ann Pinkerton

Investor Contact:
NanoLogix, Inc.
Investor Relations
Carol Surrena
Telephone: 330-534-0800

Copyright 2011 NanoLogix, Inc All Rights Reserved